152 related articles for article (PubMed ID: 37318131)
1. Comparison of Different
Dülger O; Öz B
Balkan Med J; 2023 Sep; 40(5):344-350. PubMed ID: 37318131
[TBL] [Abstract][Full Text] [Related]
2. ROS1 rearrangements in non-small cell lung cancer: screening by immunohistochemistry using proportion of cells staining without intensity and excluding cases with MAPK pathway drivers improves test performance.
Prall OWJ; Browning J; Nastevski V; Caporarello S; Bates B; Hewitt CA; Arenas A; Lamb G; Howlett K; Arnolda R; Adeloju R; Stuart S; Xu H; Fellowes A; Fox SB
Pathology; 2022 Apr; 54(3):279-285. PubMed ID: 34635319
[TBL] [Abstract][Full Text] [Related]
3. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study.
Conde E; Hernandez S; Martinez R; Angulo B; De Castro J; Collazo-Lorduy A; Jimenez B; Muriel A; Mate JL; Moran T; Aranda I; Massuti B; Rojo F; Domine M; Sansano I; Garcia F; Felip E; Mancheño N; Juan O; Sanz J; Gonzalez-Larriba JL; Atienza-Cuevas L; Arriola-Arellano E; Abdulkader I; Garcia-Gonzalez J; Camacho C; Rodriguez-Abreu D; Teixido C; Reguart N; Gonzalez-Piñeiro A; Lazaro-Quintela M; Lozano MD; Gurpide A; Gomez-Roman J; Lopez-Brea M; Pijuan L; Salido M; Arriola E; Company A; Insa A; Esteban-Rodriguez I; Saiz M; Azkona E; Alvarez R; Artal A; Plaza ML; Aguiar D; Enguita AB; Benito A; Paz-Ares L; Garrido P; Lopez-Rios F
J Thorac Oncol; 2019 Dec; 14(12):2120-2132. PubMed ID: 31349061
[TBL] [Abstract][Full Text] [Related]
4. Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients.
Hofman V; Rouquette I; Long-Mira E; Piton N; Chamorey E; Heeke S; Vignaud JM; Yguel C; Mazières J; Lepage AL; Bibeau F; Begueret H; Lassalle S; Lalvée S; Zahaf K; Benzaquen J; Poudenx M; Marquette CH; Sabourin JC; Ilié M; Hofman P
J Thorac Oncol; 2019 Jul; 14(7):1204-1212. PubMed ID: 30999109
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a new diagnostic immunohistochemistry approach for ROS1 rearrangement in non-small cell lung cancer.
Wang W; Cheng G; Zhang G; Song Z
Lung Cancer; 2020 Aug; 146():224-229. PubMed ID: 32580101
[TBL] [Abstract][Full Text] [Related]
6. Correlation of ROS1 Immunohistochemistry With
Huang RSP; Smith D; Le CH; Liu WW; Ordinario E; Manohar C; Lee M; Rajamani J; Truong H; Li J; Choi C; Li J; Pati A; Bubendorf L; Buettner R; Kerr KM; Lopez-Rios F; Marchetti A; Marondel I; Nicholson AG; Öz AB; Pauwels P; Penault-Llorca F; Rossi G; Thunnissen E; Newell AH; Pate G; Menzl I
Arch Pathol Lab Med; 2020 Jun; 144(6):735-741. PubMed ID: 31509456
[TBL] [Abstract][Full Text] [Related]
7. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
[TBL] [Abstract][Full Text] [Related]
8. Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer.
Cheung CC; Smith AC; Albadine R; Bigras G; Bojarski A; Couture C; Cutz JC; Huang WY; Ionescu D; Itani D; Izevbaye I; Karsan A; Kelly MM; Knoll J; Kwan K; Nasr MR; Qing G; Rashid-Kolvear F; Sekhon HS; Spatz A; Stockley T; Tran-Thanh D; Tucker T; Waghray R; Wang H; Xu Z; Yatabe Y; Torlakovic EE; Tsao MS
Lung Cancer; 2021 Oct; 160():127-135. PubMed ID: 34509095
[TBL] [Abstract][Full Text] [Related]
9. "Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer".
Dyrbekk APH; Warsame AA; Suhrke P; Ludahl MO; Moe JO; Eide IJZ; Lund-Iversen M; Brustugun OT
Diagn Pathol; 2023 May; 18(1):70. PubMed ID: 37237384
[TBL] [Abstract][Full Text] [Related]
10. Histologic and Molecular Characterization of Non-Small Cell Lung Carcinoma With Discordant ROS1 Immunohistochemistry and Fluorescence In Situ Hybridization.
Wilcock DM; Schmidt RL; Furtado LV; Matynia AP; Deftereos G; Sirohi D
Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):19-26. PubMed ID: 34534989
[TBL] [Abstract][Full Text] [Related]
11. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
Selinger CI; Li BT; Pavlakis N; Links M; Gill AJ; Lee A; Clarke S; Tran TN; Lum T; Yip PY; Horvath L; Yu B; Kohonen-Corish MR; O'Toole SA; Cooper WA
Histopathology; 2017 Feb; 70(3):402-411. PubMed ID: 27599111
[TBL] [Abstract][Full Text] [Related]
12. Comparison of ROS1-rearrangement detection methods in a cohort of surgically resected non-small cell lung carcinomas.
Thurfjell V; Micke P; Yu H; Krupar R; Svensson MA; Brunnström H; Lamberg K; Moens LNJ; Strell C; Gulyas M; Helenius G; Yoshida A; Goldmann T; Mattsson JSM
Transl Lung Cancer Res; 2022 Dec; 11(12):2477-2494. PubMed ID: 36636421
[TBL] [Abstract][Full Text] [Related]
13. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
[TBL] [Abstract][Full Text] [Related]
14. A genomic and clinicopathological study of non-small-cell lung cancers with discordant ROS1 gene status by fluorescence in-situ hybridisation and immunohistochemical analysis.
Zhao J; Chen X; Zheng J; Kong M; Wang B; Ding W
Histopathology; 2018 Jul; 73(1):19-28. PubMed ID: 29464758
[TBL] [Abstract][Full Text] [Related]
15. FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry 'Equivocal' interpretation category in the Ventana anti-ALK (D5F3) CDx assay - A tertiary cancer center experience.
Singh A; Kumar R; Shetty O; Desai S; Rane S
Indian J Cancer; 2022; 59(1):18-25. PubMed ID: 33402590
[TBL] [Abstract][Full Text] [Related]
16. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.
Sholl LM; Sun H; Butaney M; Zhang C; Lee C; Jänne PA; Rodig SJ
Am J Surg Pathol; 2013 Sep; 37(9):1441-9. PubMed ID: 23887156
[TBL] [Abstract][Full Text] [Related]
17. Validation of ROS1 by immunohistochemistry against fluorescent in situ hybridisation on cytology and small biopsy samples in a large teaching hospital.
Narine N; Wallace A; Dore J; O'Leary-Jackson S; Al Najjar H; Bailey S; Khan K; Teng B; Qasim M; Shelton D; Holbrook M; Abbasi S; Carter M; Irion L; Al-Habba S; Lindsay C; Blackhall F; Rana D
Cytopathology; 2021 Sep; 32(5):621-630. PubMed ID: 34033159
[TBL] [Abstract][Full Text] [Related]
18. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
[TBL] [Abstract][Full Text] [Related]
19. Detection of ROS1-positive non-small cell lung cancer on cytological specimens using immunocytochemistry.
Vlajnic T; Savic S; Barascud A; Baschiera B; Bihl M; Grilli B; Herzog M; Rebetez J; Bubendorf L
Cancer Cytopathol; 2018 Jun; 126(6):421-429. PubMed ID: 29451745
[TBL] [Abstract][Full Text] [Related]
20. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
Rogers TM; Russell PA; Wright G; Wainer Z; Pang JM; Henricksen LA; Singh S; Stanislaw S; Grille J; Roberts E; Solomon B; Fox SB
J Thorac Oncol; 2015 Apr; 10(4):611-8. PubMed ID: 25789833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
